CAPR
Capricor Therapeutics, Inc.
$22.25
+0.03 (+0.14%)
At close · Jul 8
Market Cap
$1.30B
Shares
57,911,893
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2025
Net Income
-$105.04M
-159.6%
FY2025
Operating Margin
-191.12%
-95.5pp
FY2024
Diluted EPS
-$2.26
-96.5%
FY2025
Operating Cash Flow
-$69.81M
-74.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $22.27M | $25.18M | $2.55M | $244.9K | $310.25K | $1.01M | $1.67M | $2.67M | $4M | $5.52M | $4.79M | $503.23K | $2.03M | $1.35M | — | — | — | — | — | |
| $92.92M | $84.45M | $49.97M | $36.45M | $21.82M | $13.57M | $8.46M | $5.14M | $12.07M | $10.77M | $16.04M | $13.76M | $7.79M | $5.2M | $2.63M | $4.14M | $4.08M | — | — | — | — | |
| $27.02M | $23.69M | $14.87M | $12.81M | $10.43M | $7.61M | $5.54M | $3.6M | $4.93M | $4.76M | $4.93M | $4.37M | $3.02M | $2.21M | $1.36M | $2.12M | $2.21M | — | — | — | — | |
| — | — | — | — | $0 | $2165 | $4330 | $43.28K | $43.28K | $49.21K | $48.75K | $48.75K | $10.73K | $11.05K | $4330 | — | — | — | — | — | — | |
| — | $1.89M | $1.43M | $1.07M | $533.13K | $245.7K | $143.89K | $171.96K | $157.65K | $144.17K | $125.72K | $110.87K | $41.9K | $26.92K | $20.34K | $7507 | $12.93K | — | — | — | — | |
| $119.93M | $108.14M | $64.83M | $49.26M | $32.25M | $21.18M | $14M | $8.74M | $17M | $15.53M | $20.98M | $18.13M | $10.8M | $7.41M | $4M | $6.25M | $6.29M | — | — | — | — | |
| -$119.93M | -$108.14M | -$42.56M | -$24.08M | -$29.7M | -$20.94M | -$13.69M | -$7.73M | -$15.33M | -$12.86M | -$16.98M | -$12.61M | -$6.02M | -$6.9M | -$2.1M | -$4.9M | -$6.29M | — | — | — | — | |
| — | — | -191.12% | -95.63% | -1163.93% | -8549.86% | -4412.56% | -769.52% | -917.04% | -482.4% | -424.56% | -228.57% | -125.72% | -1371.71% | -103.34% | -361.7% | — | — | — | — | — | |
| — | -$106.25M | -$41.14M | -$23.01M | -$29.16M | -$20.69M | -$13.55M | -$7.56M | -$15.17M | -$12.72M | -$16.85M | -$12.5M | -$5.98M | -$6.88M | -$2.08M | -$4.89M | -$6.28M | — | — | — | — | |
| — | $3.05M | $0 | — | — | — | — | — | $0 | $398.81K | $344.67K | $248.63K | $200.51K | $58.13K | $0 | $0 | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $795.19K | $6006 | $20.38K | — | — | — | — | |
| $5.34M | $3.1M | $2.1M | $1.79M | $677.85K | $915.92K | $32.94K | $92.07K | $135.99K | $15.29M | -$1.83M | -$245.51K | -$198.61K | -$1.99M | $28.79K | $14.39K | $262.06K | — | — | — | — | |
| — | -$105.04M | -$40.47M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $1600 | $1600 | — | — | — | — | — | — | — | — | — | — | — | $0 | — | — | — | — | — | — | |
| -$114.59M | -$105.04M | -$40.47M | -$22.29M | -$29.02M | -$20.02M | -$13.66M | -$7.64M | -$15.19M | $2.43M | -$18.81M | -$12.86M | -$6.22M | -$8.89M | -$2.07M | -$1.15M | -$1.06M | -$148.97K | -$630.86K | -$979.08K | -$1.17M | |
| — | — | -181.71% | -88.52% | -1137.37% | -8175.86% | -4401.94% | -760.36% | -908.91% | 91.19% | -470.33% | -233.02% | -129.87% | -1766.96% | -101.92% | -84.85% | — | — | — | — | — | |
| -$116.66M | -$105.79M | -$39.68M | -$22.16M | -$28.91M | -$20.02M | -$13.66M | -$7.65M | -$15.19M | $2.44M | -$18.81M | -$12.85M | -$6.22M | -$8.87M | -$21.8K | — | — | — | — | — | — | |
| USD/shares | — | -$2.26 | -$1.15 | -$0.83 | -$1.18 | -$0.87 | -$0.88 | — | — | $0.10 | -$1.01 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$2.26 | -$1.15 | -$0.83 | -$1.18 | -$0.87 | -$0.88 | — | -$0.52 | $0.09 | -$1.01 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 46.48M | 35.22M | 26.78M | 24.55M | 23.09M | 15.57M | 3.71M | 2.94M | 23.19M | 18.55M | 15.9M | 11.7M | 10.5M | 9.95M | 37.33M | — | — | — | — | — |
| shares | — | 46.48M | 35.22M | 26.78M | 24.55M | 23.09M | 15.57M | 3.71M | 2.94M | 26.79M | 18.55M | 15.9M | 11.7M | 10.5M | 9.95M | 37.33M | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2020: $193 in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Biotechnology median 7.68×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2024-12-31 |
|---|---|
| Single Reportable Segment | $22,270,465 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Single Reportable Segment | -$108,142,130 | -$42,563,242 |
Operating Margin by Segment (%)
| Component | 2024-12-31 |
|---|---|
| Single Reportable Segment | -191.1% |